Evaluation of anxiety and depression in patients with morphea taking immunosuppressive drugs during the COVID-19 pandemic
Background During the coronavirus disease 2019 (COVID-19) pandemic, individuals especially those with chronic diseases face various problems like psychological distress. Aim To evaluate anxiety and depression among morphea patients taking immunosuppressants compared with controls during the COVID-19...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-04-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2020.1819528 |
| _version_ | 1797683554109358080 |
|---|---|
| author | Mohammad Shahidi Dadras Zohreh Ahmadzadeh Shima Younespour Fahimeh Abdollahimajd |
| author_facet | Mohammad Shahidi Dadras Zohreh Ahmadzadeh Shima Younespour Fahimeh Abdollahimajd |
| author_sort | Mohammad Shahidi Dadras |
| collection | DOAJ |
| description | Background During the coronavirus disease 2019 (COVID-19) pandemic, individuals especially those with chronic diseases face various problems like psychological distress. Aim To evaluate anxiety and depression among morphea patients taking immunosuppressants compared with controls during the COVID-19 pandemic. Methods In this case-control study, electronic data of 42 eligible morphea patients and 42 age- and sex-matched healthy subjects were extracted. All participants were asked about adherence to the health protocols and the symptoms of COVID-19. To investigate anxiety and depression, we provided the participants with an online version of the Hospital Anxiety and Depression Scale (HADS) Questionnaire. In this standard questionnaire, a score ≥ 11 represents a significant psychological disorder. Results The two groups did not differ significantly in the mean HADS-Anxiety (HADS-A) and HADS-Depression (HADS-D) scores (p= .08 and p= .79, respectively). HADS-A and HADS-D scores were ≥ 11 in 16.67% and 11.90% of the patients, respectively. Among the morphea patients, those with sleeping problems during COVID-19 had a significantly higher mean HADS-D score (p= .048). Notably, 21.43% of patients discontinued their treatment due to fear of COVID-19 and experienced disease recurrence. Adherence to health protocols was higher in patients compared with controls. The rate of COVID-19 occurrence was not significantly different between the groups. Conclusions Although there was no significant difference in anxiety and depression between the groups, it is recommended to provide psychiatric counseling opportunities to morphea patients to improve treatment outcomes during this pandemic. |
| first_indexed | 2024-03-12T00:15:54Z |
| format | Article |
| id | doaj.art-5200e285a52a4a3d9d9260cfe62e3742 |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:15:54Z |
| publishDate | 2022-04-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-5200e285a52a4a3d9d9260cfe62e37422023-09-15T14:28:49ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532022-04-013331406141210.1080/09546634.2020.18195281819528Evaluation of anxiety and depression in patients with morphea taking immunosuppressive drugs during the COVID-19 pandemicMohammad Shahidi Dadras0Zohreh Ahmadzadeh1Shima Younespour2Fahimeh Abdollahimajd3Skin Research Center, Shahid Beheshti University of Medical SciencesSkin Research Center, Shahid Beheshti University of Medical SciencesDentistry Research Institute, Tehran University of Medical SciencesSkin Research Center, Shahid Beheshti University of Medical SciencesBackground During the coronavirus disease 2019 (COVID-19) pandemic, individuals especially those with chronic diseases face various problems like psychological distress. Aim To evaluate anxiety and depression among morphea patients taking immunosuppressants compared with controls during the COVID-19 pandemic. Methods In this case-control study, electronic data of 42 eligible morphea patients and 42 age- and sex-matched healthy subjects were extracted. All participants were asked about adherence to the health protocols and the symptoms of COVID-19. To investigate anxiety and depression, we provided the participants with an online version of the Hospital Anxiety and Depression Scale (HADS) Questionnaire. In this standard questionnaire, a score ≥ 11 represents a significant psychological disorder. Results The two groups did not differ significantly in the mean HADS-Anxiety (HADS-A) and HADS-Depression (HADS-D) scores (p= .08 and p= .79, respectively). HADS-A and HADS-D scores were ≥ 11 in 16.67% and 11.90% of the patients, respectively. Among the morphea patients, those with sleeping problems during COVID-19 had a significantly higher mean HADS-D score (p= .048). Notably, 21.43% of patients discontinued their treatment due to fear of COVID-19 and experienced disease recurrence. Adherence to health protocols was higher in patients compared with controls. The rate of COVID-19 occurrence was not significantly different between the groups. Conclusions Although there was no significant difference in anxiety and depression between the groups, it is recommended to provide psychiatric counseling opportunities to morphea patients to improve treatment outcomes during this pandemic.http://dx.doi.org/10.1080/09546634.2020.1819528anxietycoronavirus disease 2019covid-19depressionimmunosuppressive treatmentsars-cov-2 |
| spellingShingle | Mohammad Shahidi Dadras Zohreh Ahmadzadeh Shima Younespour Fahimeh Abdollahimajd Evaluation of anxiety and depression in patients with morphea taking immunosuppressive drugs during the COVID-19 pandemic Journal of Dermatological Treatment anxiety coronavirus disease 2019 covid-19 depression immunosuppressive treatment sars-cov-2 |
| title | Evaluation of anxiety and depression in patients with morphea taking immunosuppressive drugs during the COVID-19 pandemic |
| title_full | Evaluation of anxiety and depression in patients with morphea taking immunosuppressive drugs during the COVID-19 pandemic |
| title_fullStr | Evaluation of anxiety and depression in patients with morphea taking immunosuppressive drugs during the COVID-19 pandemic |
| title_full_unstemmed | Evaluation of anxiety and depression in patients with morphea taking immunosuppressive drugs during the COVID-19 pandemic |
| title_short | Evaluation of anxiety and depression in patients with morphea taking immunosuppressive drugs during the COVID-19 pandemic |
| title_sort | evaluation of anxiety and depression in patients with morphea taking immunosuppressive drugs during the covid 19 pandemic |
| topic | anxiety coronavirus disease 2019 covid-19 depression immunosuppressive treatment sars-cov-2 |
| url | http://dx.doi.org/10.1080/09546634.2020.1819528 |
| work_keys_str_mv | AT mohammadshahididadras evaluationofanxietyanddepressioninpatientswithmorpheatakingimmunosuppressivedrugsduringthecovid19pandemic AT zohrehahmadzadeh evaluationofanxietyanddepressioninpatientswithmorpheatakingimmunosuppressivedrugsduringthecovid19pandemic AT shimayounespour evaluationofanxietyanddepressioninpatientswithmorpheatakingimmunosuppressivedrugsduringthecovid19pandemic AT fahimehabdollahimajd evaluationofanxietyanddepressioninpatientswithmorpheatakingimmunosuppressivedrugsduringthecovid19pandemic |